IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Frieder U. MAERZ) Art Unit: 1617

U.S. Appln. No. : To be assigned) Examiner: S. Wang Confirmation No. : To be assigned U.S. Filing Date : January 30, 2004
Γitle of Invention: Stable Xylometazoline and Oxymetazoline Solution Attny. Docket No.: 1/1090-1-C1
Mail Stop Patent Application Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450
January 30, 2004
TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT
Sir:
Transmitted herewith concerning the subject application is an Information Disclosure Statement (Form 1449A/B) under 37 C.F.R. §§1.56 and 1.97, as more specifically described hereinbelow.
1.97(b). This Statement is being filed: i) within three (3) months of the filing date of a national application other than a continued prosecution application under 33 C.F.R. §1.53 (d); ii) within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; iii) before the mailing of a first Office action the merits; or iv) before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114.
1.97(c). This Statement is being filed after the time period specified in 37 C.F.R. §1.97(b), but before the mailing date of: i) a final action under 37 C.F.R. §1.113, ii) a notice of allowance under 37 C.F.R. §1.311, or iii) an action that otherwise closes prosecution the application. This Statement is being accompanied by:
A statement as specified in 37 C.F.R. §1.97(e) [see below]; or
The fee set forth in 37 C.F.R. §1.17(p).

	The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
	This Statement is being filed after the period specified in 37 C.F.R. or before payment of the issue fee. This Statement is accompanied by a scified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.
1.97(e).	
statemer counterp	Each item of information contained in the instant information disclosure at was first cited in any communication from a foreign patent office in a part foreign application not more than three (3) months prior to the filing of an information disclosure statement; or
statemer foreign a making i informat §1.56(c)	No item of information contained in the instant information disclosure at was cited in a communication from a foreign patent office in a counterpart application, and, to the knowledge of the person signing this certification after reasonable inquiry, no item of information contained in the instant tion disclosure statement was known to any individual designated in 37 C.F.R. more than three (3) months prior to the filing of the instant information re statement.
n	The fee set forth in 37 C.F.R. §1.17(p).
	The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 92-2955.
in section 1.56(c	Each item of information contained in the accompanying information ment was cited in a communication from a foreign patent office in a lication, which communication was not received by any individual designated by more than thirty (30) days prior to the filing of the accompanying closure statement.

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted

Mary-Ellen M. Devlin Attorney for Applicant(s)

Reg. No. 27,928

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877

Tel: (203) 798-4866

Certificate of Mailing

Mary-Ellen M. Devlin, Reg. No. 27,928

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Patent Application Commissioner For Patents P. O. Box 1450 Alexandria, VA 22313-1450

on January 30, 2004.

3 of 3

Approved for use through 07/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO Application Number To be assigned Filing Date INFORMATION DISCLOSURE January 30, 2004 First Named Inventor Frieder U. MAERZ STATEMENT BY APPLICANT Art Unit 1617 **Examiner Name**

S. Wang (Use as many sheets as necessary) Attorney Docket Number 1/1090-1-C1 2 1

U. S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		^{US-} 4,603,131	07/29/2986	J.E. Bernstein & C.J. Endicott			
		^{US-} 5,801,199	09/01/1998	R. Greve & H. Greve			
		^{US-} 4,970,240	11/13/1990	James R. Kielley			
		^{US-} 5,114,979A	05/19/1992	James R. Kielly			
		US-					
		US-					
		US-					
***************************************		US-					
		US-					
		US-					
······································		US-					
		US-					
***************************************		US-					
	-	US-					
***************************************	l	US-					
		US-			THE		
/*************************************	·	US-					
	1	US-					

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
		WO 99 38492 A	08/05/1999	Novartis Consumer Health S	.A.		
		HU P9700143	11/30/1998	Dr. Somi Lldko et al.			

Examiner	D	Date	
Signature	c	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for	form 1449B/PTO			Complete if Known			
				Application Number	To be assigned		
INFO	RMATION D	ISCLO	SURE	Filing Date	January 30, 2004		
STAT	TATEMENT BY APPLICANT			First Named Inventor Frieder U. MAERZ			
				Art Unit	1617		
(Use as many sheets as necessary)			•	Examiner Name	S. Wang		
Sheet	2	of	2	Attorney Docket Number	1/1090-1-C1		

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
		The Merck Index, 13th Edition, 2001, Merck & Co. Inc. pages 1247 and 1800				
••••••	ļ					

•••••						
••••••						

,						
	<u>1</u>					
Examiner		Date				

	ŀ		
Examiner	Date	1	
Signature	Considered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. Applicant is unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.